Collegium: Intact Xtampza had lower peak ‘Drug Liking’ vs. IR oxycodone

Collegium Pharmaceutical announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx formulation,” in the peer-reviewed medical journal, Journal of Opioid Management. The publication presents the results from a human abuse potential study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza ER oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers. The results demonstrated that intact and chewed Xtampza ER had statistically significantly lower peak “Drug Liking” when compared with crushed immediate-release oxycodone. Furthermore, Xtampza ER zx) and area under the curve. Intact and chewed Xtampza ER also demonstrated statistically significant lower “Take Drug Again” scores when compared with crushed immediate-release oxycodone. Additionally, statistically significant differences in peak effects between intact and chewed Xtampza ER treatments compared with crushed IR oxycodone were seen for other secondary endpoints such as “Overall Drug Liking,” “Feeling High,” “Any Drug Effects” and “Good Drug Effects.”
https://thefly.com/landingPageNews.php?id=2812409